The chronic lung inflammation that is a hallmark of cystic fibrosis, has, for the first time, been linked to a new class of bacterial enzymes that hijack the patient’s immune response and prevent the body from calling off runaway inflammation, according to a laboratory investigation led by the University of Pittsburgh School of Medicine.
A pair of Vanderbilt chemists have developed a faster, cheaper method for synthesizing ring molecules called cyclic depsipeptides found in antibiotics, anti-retrovirals and pesticides.
UT Southwestern Medical Center researchers have found that intermittent fasting inhibits the development and progression of the most common type of childhood leukemia.
ROCHESTER, Minn. — Researchers at Mayo Clinic have identified an enzyme called UCHL3 that regulates the BRCA2 pathway, which is important for DNA repair. Results of this research are published online in Genes & Development.
A major challenge in truly targeted cancer therapy is cancer’s suppression of the immune system. Northwestern University synthetic biologists now have developed a general method for “rewiring” immune cells to flip this action around. When cancer is present, molecules secreted at tumor sites render many immune cells inactive. The Northwestern researchers genetically engineered human immune cells to sense the tumor-derived molecules in the immediate environment and to respond by becoming more active, not less.
A study embargoed until Monday, 12/12 shows that a protein biomarker for chronic kidney disease originates in the bone marrow. This discovery of where the suPAR protein originates is an important step towards earlier detection –and possible prevention – of a disease suffered by one in 10 adults, kills 48,000 people and costs Medicare $49 billion each year.
Members of the TET family of proteins help protect against cancer by regulating the chemical state of DNA —and thus turning growth-promoting genes on or off. The latest findings reported by researchers at La Jolla Institute for Allergy and Immunology illustrate just how important TET proteins are in controlling cell proliferation and cell fate.
Even short-term blockages in hearing can lead to remarkable changes in the auditory system, altering the behavior and structure of nerve cells that relay information from the ear to the brain, according to a new University at Buffalo study.
A genetic discovery by a team led by Dianna Milewicz, M.D., Ph.D., of The University of Texas Health Science Center at Houston (UTHealth) could help explain a cause of a mysterious artery-damaging disease that may affect up to an estimated 5 million Americans and often strikes without warning.
New research led by scientists at The Scripps Research Institute (TSRI) reveals that a human enzyme has changed little from its days as a bacterial enzyme.
Truncated p53 proteins, presumed unimportant, now point to new drug targets for some of 'the hardest cancers'
Most cancer treatments come in the form of chemotherapy given intravenously. This is unique because it uses a combination of two oral medications.
Blood-forming stem cells are able to count and store memories of the number of times that they divide, findings which could have major implications for disease research, scientists at the Icahn School of Medicine at Mount Sinai have found.
A team of scientists has uncovered details of the cellular mechanisms that control the direct programming of stem cells into motor neurons.
Results of the largest Canadian clinical trial to date comparing standard treatment for locally advanced squamous cell head and neck cancer with an experimental treatment, did not show the new treatment is superior.
Researchers cracked the complete genetic code of individual cells in healthy and diseased human lung tissues to find potential new molecular targets for diagnosing and treating the lethal lung disease Idiopathic Pulmonary Fibrosis (IPF). Scientists from Cincinnati Children’s Hospital Medical Center, in collaboration with investigators at Cedars-Sinai Medical Center in Los Angeles, publish their findings Dec. 8 in the Journal of Clinical Investigation Insights (JCI Insight).
Technion researchers have discovered a biological pathway that plays an important role in tumor development. The findings could lead to cancer-fighting drugs that work by shortening the half-life of select cancer-promoting proteins known as oncoproteins.
Researchers at the Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego have now determined the 3D structure of CCR2 simultaneously bound to two inhibitors. Understanding how these molecules fit together may better enable pharmaceutical companies to develop anti-inflammatory drugs that bind and inhibit CCR2 in a similar manner. The study is published December 7 by Nature.
Scientists have called superoxide out as the main culprit behind coral bleaching: The idea is that as this toxin build up inside coral cells, the corals fight back by ejecting the tiny energy- and color-producing algae living inside them. In doing so, they lose their vibrancy, turn a sickly white, and are left weak, damaged, and vulnerable to disease.
Leukemia researchers at Princess Margaret Cancer Centre have developed a 17-gene signature derived from leukemia stem cells that can predict at diagnosis if patients with acute myeloid leukemia (AML) will respond to standard treatment.
The fate of stem cells is determined by series of choices that sequentially narrow their available options until stem cells’ offspring have found their station and purpose in the body. Their decisions are guided in part by TET proteins rewriting the epigenome, the regulatory layer of chemical flags that adorn the genome and influence gene activity, report researchers at La Jolla Institute for Allergy and Immunology and UC San Diego.
Researchers from the Cedars-Sinai Heart Institute and the Cedars-Sinai Department of Medicine are expanding their ongoing evaluation of a novel cell-based therapeutic candidate into the area of pulmonary arterial hypertension (PAH). This work will be supported by a recently-awarded $7.3 million grant from the California Institute for Regenerative Medicine.
The blood-brain barrier is a network of specialized cells that surrounds the arteries and veins within the brain. It forms a unique gateway that both provides brain cells with the nutrients they require and protects them from potentially harmful compounds. An interdisciplinary team of researchers from the Vanderbilt Institute for Integrative Biosystems Research and Education (VIIBRE) headed by Gordon A.
Researchers at UT Southwestern Medical Center have found a new biomarker for glioma, a common type of brain cancer, that can help doctors determine how aggressive a cancer is and that could eventually help determine the best course of treatment.
The patent relates to the use of Streck’s proprietary Cell-Free DNA BCT CE product for the collection of samples to analyze fetal nucleic acid for non-invasive prenatal testing (NIPT).
Researchers found that the browning program in white fat cells is normally suppressed by a protein called FLCN. It performs this function in cooperation with a major cellular signaling hub, a protein complex known as mTOR. Harnessing this knowledge may one day provide the key to better treatments for obesity.
Demonstration that bacteria can drive mating in eukaryotes raises possibility that environmental bacteria or bacterial symbionts may influence mating in animals
The combination of two new drugs that harness the body’s immune system is safe and effective, destroying most cancer cells in 64 percent of patients with recurrent Hodgkin lymphoma, according to the results of an early-phase study.
Fred Hutchinson Cancer Research Center announced promising results from an early trial in which patients with high-risk acute myeloid leukemia received genetically engineered immune cells. Of the 12 AML patients who received this experimental T-cell therapy after a transplant put their disease in remission, all are still in remission after a median follow-up of more than two years.
Researchers at the University of Wisconsin-Madison have developed a novel strategy to reprogram cells from one type to another in a more efficient and less biased manner than previous methods.
UCLA scientists provides further evidence that the brains of people with autism, despite different causes, tend to have the same molecular “signature.”
In a recent study, a Yale Cancer Center team confirmed expectations of higher healthcare utilization and costs with relapsed Diffuse Large B-Cell Lymphoma (DLBCL).
A team of researchers, co-led by a University of California, Riverside professor, has found a long-sought-after mechanism in human cells that creates immunity to influenza A virus, which causes annual seasonal epidemics and occasional pandemics.
TAMPA, Fla. – Immune cellular therapy is a promising new area of cancer treatment. Anti-cancer therapeutics, such as chimeric antigen receptor (CAR) modified T cells, can be engineered to target tumor-associated antigens to attack and kill cancer cells. This allows for an improved precision medicine approach to treating cancer.
The University of Arkansas for Medical Sciences (UAMS) is collaborating with Dana-Farber Cancer Institute and Celgene Corp. to compile the largest set of high-quality
Riding a wave of powerful new imaging technologies, three ASCB member labs will take you inside the world of living cells with the release of three short 2016 Celldance videos at the ASCB Annual Meeting in San Francisco
Stephen Elledge, the Gregor Mendel Professor of Genetics and of Medicine at Brigham and Women’s Hospital and Harvard Medical School, has been named a 2017 recipient of the Breakthrough Prize, which recognizes paradigm-shifting discoveries in the life sciences, physics and mathematics. Elledge is being honored for his wide-ranging contributions across multiple fields in biology.
A highly innovative, personalized cell-based treatment for a high-risk form of the most common childhood cancer continues to move through clinical trials. Pediatric oncologists from Children’s Hospital of Philadelphia (CHOP) today reported new results using T cell immunotherapy against relapsed or refractory acute lymphoblastic leukemia (ALL).
In a small, early phase trial, a high percentage of patients who had exhausted most traditional treatments for chronic lymphocytic leukemia saw their tumors shrink or even disappear after an infusion of a highly targeted, experimental CAR T-cell immunotherapy developed at Seattle’s Fred Hutchinson Cancer Research Center.
ASCB names 10 "Novel & Newsworthy" Honor abstracts out of 1263 being presented in San Francisco, Dec. 3-7
Researchers from the Perelman School of Medicine at the University of Pennsylvania and The Children’s Hospital of Philadelphia (CHOP) will present the latest advances from their studies of personalized cellular therapies for blood cancers during the 58th Annual Meeting of the American Society of Hematology (ASH) in San Diego.
Research team has discovered an important molecular link between a rare childhood genetic disease and a major cancer gene. The discovery could lead to improved treatment outcomes for some cancer patients.
The Monell Center announced today that it has received a $345,000 grant from the Bill & Melinda Gates Foundation. The grant supports an innovative global health research project titled, "Developing Novel Pediatric Formulation Technologies for Global Health: Human Taste Assays."
Researchers led by scientists at Dana-Farber Cancer Institute say they have identified unique genomic changes that may be integral to testicular cancer development and explain why the great majority are highly curable with chemotherapy – unlike most solid tumors.
Previous studies identified the Hippo pathway kinases LATS1/2 as a tumor suppressor, but new research led by University of California San Diego School of Medicine scientists reveals a surprising role for these enzymes in subduing cancer immunity. The findings could have a clinical role in improving efficiency of immunotherapy drugs.
Scientists from the Institute of Molecular Biotechnology (IMBA) in Vienna, Austria, have discovered how an embryo’s genomic integrity is safeguarded during the first 24 h after fertilization. Insights into this mechanism have implications for improving in vitro fertilization.
PHILADELPHIA—An existing drug known as a JAK inhibitor may help patients who don’t respond to the so-called checkpoint inhibitor immunotherapy drugs overcome that resistance, suggests a new preclinical study published online in Cell today by Penn Medicine researchers. Importantly, the results demonstrate that shutting down the interferon pathway, shown here to be critical to a tumor’s resistance to immunotherapy, with a JAK inhibitor may improve checkpoint inhibitor drugs and even bypass the need for combinations of these drugs, which often come with serious side effects.
Mayo Clinic Monthly News Tips — November 2016
The Bill & Melinda Gates Foundation has awarded an $8,777,578 million grant to The Wistar Institute to create a preventative Zika therapy utilizing synthetic DNA monoclonal antibodies (dMAbs).
The study, “A Real-World Multicentre Retrospective Observational Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line Treatment for HER2-Negative Metastatic Breast Cancer,” was recently published in the Journal of Cell Physiology.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right